Halozyme Therapeutics reported better-than-expected Q1 2026 earnings, reaffirmed its 2026–2028 guidance, and announced a new $1 billion share repurchase program. The company continues to generate strong royalty revenue growth and maintains high gross margins above 75%, supporting strong free cash flow. Despite these strengths, Halozyme shares trade at a notable discount compared to historical and sector valuations. The analyst values the stock at $74.30 per share, citing its double-digit royalty growth, high capital returns, and a promising product pipeline as key drivers of shareholder value.
Shirofune has introduced Walmart Connect, an integration that allows advertisers and agencies to manage Walmart retail media campaigns alongside other digital channels within a single platform. This automation reduces manual bid adjustments and repor...
Purecore Metals Inc. has signed a non-binding letter of intent with Skyharbour Resources to acquire an option to earn up to 100% interest in the Yurchison uranium property in Saskatchewan's Athabasca Basin. The property covers over 35,000 hectares an...
Point completed a $508.6 million rated asset-backed securitization of its Home Equity Investment (HEI) assets, marking the largest transaction ever in the HEI asset class. The deal attracted over 30 institutional investors and priced at significantly...
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
Cardano has introduced native support for BLS12-381 elliptic curve cryptography in its Plutus smart contracts, enabling the verification of thousands of signatures on-chain at a low and predictable cost. This technology compresses multiple signatures...
